AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.
AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.
Swiss drugmaker Roche Holding AG’s U.S. unit Genentech Inc. won approval for the immunotherapy Tecentriq for a tough-to-treat type of lung cancer.
Eli Lilly and Co.’s combination cancer treatment met the main goal of a late-stage clinical trial in testing on patients with a form of lung cancer, the drugmaker announced.
Roche received European Commission (EC) approval for the company’s Tecentriq drug in combination with Avastin and chemo as an initial treatment for people with a specific type of lung cancer.
Researchers are having a hard time getting their hands on specimens for their work on new treatments, diagnostics, and cures.
Nektar Therapeutics said some patients with advanced bladder cancer treated with a combination of the company’s experimental treatment and Bristol-Myers Squibb’s immunotherapy Opdivo showed signs of tumor reduction in an early-stage study.
Clinigen Group Plc said the British pharmaceutical firm acquired the U.S. rights to Swiss drugmaker Novartis AG’s skin and lung cancer drug Proleukin for a total of $210 million, including some future payments.
GlaxoSmithKline bolstered the company’s cancer drug development pipeline, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Merck KGaA for the rights to a next-generation immunotherapy.